惠泰医疗
(688617)
| 流通市值：384.96亿 | | | 总市值：384.96亿 |
| 流通股本：1.42亿 | | | 总股本：1.42亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,358,012,259.82 | 1,526,351,745.77 | 704,078,336.74 | 2,583,927,321.09 |
| 营业收入 | 2,358,012,259.82 | 1,526,351,745.77 | 704,078,336.74 | 2,583,927,321.09 |
| 二、营业总成本 | 1,459,626,632.52 | 946,822,836.62 | 451,345,627.26 | 1,672,065,165.22 |
| 营业成本 | 629,815,725.92 | 412,470,194.36 | 194,140,326.74 | 700,841,947.49 |
| 税金及附加 | 31,041,697.02 | 19,858,964.51 | 9,664,275.09 | 33,678,934.77 |
| 销售费用 | 369,938,185.42 | 239,343,152.79 | 114,613,851.13 | 460,613,793.02 |
| 管理费用 | 100,566,299.44 | 67,707,175.62 | 32,844,888.35 | 118,637,495.73 |
| 研发费用 | 315,249,897.64 | 196,698,473.19 | 95,376,771.98 | 364,801,511.35 |
| 财务费用 | 13,014,827.08 | 10,744,876.15 | 4,705,513.97 | -6,508,517.14 |
| 其中:利息费用 | 908,263.69 | 621,509.61 | 520,339.46 | 1,460,385.06 |
| 其中:利息收入 | 7,397,589.14 | 5,108,418.49 | 2,786,983.28 | 13,794,942.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,878,703.1 | 587,824.69 | 1,007,830.77 | 485,745.67 |
| 加:投资收益 | 27,610,503.8 | 19,514,195.06 | 9,664,031.12 | 16,938,228.6 |
| 资产处置收益 | -289,116.4 | -336,235.71 | -334,654.01 | -926,856.07 |
| 资产减值损失(新) | -6,104,883.16 | -6,091,104.74 | -4,203,589.85 | -6,547,893.55 |
| 信用减值损失(新) | -193,311.34 | 1,111,070.69 | 2,042,026.91 | -16,591,722.12 |
| 其他收益 | 12,038,764.47 | 9,749,741.14 | 4,733,739.88 | 39,338,897.44 |
| 四、营业利润 | 934,326,287.77 | 604,064,400.28 | 265,642,094.3 | 944,558,555.84 |
| 加:营业外收入 | 162,998 | 48,610.63 | 40,895.47 | 184,843.14 |
| 减:营业外支出 | 2,097,108.05 | 903,303.26 | 155,710.39 | 8,452,999.47 |
| 五、利润总额 | 932,392,177.72 | 603,209,707.65 | 265,527,279.38 | 936,290,399.51 |
| 减:所得税费用 | 126,333,548.32 | 75,350,791.46 | 39,765,232.46 | 128,551,192.99 |
| 六、净利润 | 806,058,629.4 | 527,858,916.19 | 225,762,046.92 | 807,739,206.52 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 806,058,629.4 | 527,858,916.19 | 225,762,046.92 | 807,739,206.52 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 818,213,774.83 | 537,319,119.8 | 229,438,737.11 | 820,636,582.43 |
| 少数股东损益 | -12,155,145.43 | -9,460,203.61 | -3,676,690.19 | -12,897,375.91 |
| 扣除非经常损益后的净利润 | 806,212,141.96 | 528,771,505.05 | 225,164,622.94 | 790,875,930.28 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 5.87 | 3.82 | 1.64 | 5.82 |
| (二)稀释每股收益 | 5.87 | 3.82 | 1.63 | 5.8 |
| 八、其他综合收益 | 530,248.6 | 795,464 | -454,815.08 | 406,783.21 |
| 归属于母公司股东的其他综合收益 | 580,847.61 | 846,063.01 | -454,815.08 | 99,330.36 |
| 九、综合收益总额 | 806,588,878 | 528,654,380.19 | 225,307,231.84 | 808,145,989.73 |
| 归属于母公司股东的综合收益总额 | 818,794,622.44 | 538,165,182.81 | 228,983,922.03 | 820,735,912.79 |
| 归属于少数股东的综合收益总额 | -12,205,744.44 | -9,510,802.62 | -3,676,690.19 | -12,589,923.06 |
| 公告日期 | 2026-10-29 | 2026-08-20 | 2026-04-24 | 2026-03-25 |
| 审计意见(境内) | | | | 标准无保留意见 |